U.S. flag

An official website of the United States government

Display Settings:

Items per page

PMC Full-Text Search Results

Items: 7

2.
Figure 2

Figure 2. Physicochemical characterization of purified Affitoxin. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.

A. 50 μg of purified Affitoxin was resolved in 4–12% Bis-Tris polyacrylamide gel along with pre-stained protein weight standards. B. MALDI-TOF MS of purified Affitoxin.

Rafal Zielinski, et al. J Immunother. ;32(8):817-825.
3.
Figure 7

Figure 7. Affitoxin efficacy in the presence of Affibody excess. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.

BT474 cells were treated with 2pM Affioxin in presence of 100nM Affibody and 100nM BSA. Cells were incubated for 72 hours and cell viability was measured using CellTiter-Glo. x

Rafal Zielinski, et al. J Immunother. ;32(8):817-825.
4.
Figure 6

Figure 6. Effect of exposure time on Affitoxin efficacy. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.

BT474 cells were treated with 43.5 pM Affitoxin for indicated time periods. After that medium containing Affitoxin was changed and incubation was continued up to 72 hours and cell viability was measured using CellTiter-Glo.

Rafal Zielinski, et al. J Immunother. ;32(8):817-825.
5.
Figure 3

Figure 3. Kinetic analysis of ZHER2:342 Affibody molecule (A) or Affitoxin (B) binding to HER2/Fc-covered surface. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.

Binding of 0.32, 0.63, 1.25, 2.5, 5 nM wild type ZHER2:342 Affibody molecule (A) and 6.17, 18.5, 55.5, 166.6, 500 nM of Affitoxin (B) to HER2/Fc on the sensor chip was tested using SPR-based binding assay. The red lines represent a global analysis of data using a Langmuir binding model. The Affibody molecule-HER2/Fc complex was allowed to dissociate for 2000 seconds in order to observe a measurable decayKinetic analysis of ZHER2:342 Affibody molecule (A) or Affitoxin (B) binding to HER2/Fc-covered surface. Kinetic data are summarized in C.

Rafal Zielinski, et al. J Immunother. ;32(8):817-825.
6.
Figure 4

Figure 4. Specificity of Affitoxin binding confirmed by confocal imaging and flow cytometry. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.

A. Cells were incubated with 0.1 μM of Alexa Fluor® 488-labeled Affitoxin for 6 hours with and without Affibody molecules. B. HER2 expression level in five different breast cancer cell lines was determined by ELISA and is expressed in nanograms of HER2 per milligram of protein lysate. Cells were incubated with 5 μg/ml of Alexa Fluor® 488-labeled Affitoxin. Binding efficacy was determined by flow cytometry. C. BT474 cells were incubated with 5 μg/ml of Alexa Fluor® 488-labeled Affitoxin and increasing concentrations of Affibody. Binding efficacy was determined by flow cytometry and quantified by GraphPad software.

Rafal Zielinski, et al. J Immunother. ;32(8):817-825.
7.
Figure 5

Figure 5. Efficacy of Affitoxin measured by inhibition of protein synthesis (A) and intracellular ATP level (B). From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.

Five different breast cancer cells lines were transfected with pCMV-GLuc plasmid containing secreted Gaussia luciferase gene under control of strong CMV promoter. Gaussia luciferase activity was measured in the medium 24 hours after treatment with Affitoxin. The same cell lines were assessed for intracellular ATP level 72 hours following treatment (CellTiter-Glo, Promega).

Rafal Zielinski, et al. J Immunother. ;32(8):817-825.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center